Results 1 to 10 of about 46,296 (214)

Multi-Pathway Study for Oxaliplatin Resistance Reduction [PDF]

Current Issues in Molecular Biology
Chemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, and other side effects, platinum-based medications ...
Tong Ye, Chen Wu, Jintong Na, Xiyu Liu, Yong Huang   +4 more
doaj   +4 more sources

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2 [PDF]

Molecular Therapy: Oncolytics, 2021
Although oxaliplatin is an effective chemotherapeutic drug commonly used for colorectal cancer (CRC) treatment, drug resistance usually occurs during the long-term use of it.
Wei Sun, Yang Ge, Junpeng Cui, Yifan Yu, Baolin Liu   +4 more
doaj   +3 more sources

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. [PDF]

PLoS ONE, 2017
The formation of acquired drug resistance is a major reason for the failure of anti-cancer therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell line
Emily Saintas, Liam Abrahams, Gulshan T Ahmad, Anu-Oluwa M Ajakaiye, Abdulaziz S H A M AlHumaidi, Candice Ashmore-Harris, Iain Clark, Usha K Dura, Carine N Fixmer, Chinedu Ike-Morris, Mireia Mato Prado, Danielle Mccullough, Shishir Mishra, Katia M U Schöler, Husne Timur, Maxwell D C Williamson, Markella Alatsatianos, Basma Bahsoun, Edith Blackburn, Catherine E Hogwood, Pamela E Lithgow, Michelle Rowe, Lyto Yiangou, Florian Rothweiler, Jindrich Cinatl, Richard Zehner, Anthony J Baines, Michelle D Garrett, Campbell W Gourlay, Darren K Griffin, William J Gullick, Emma Hargreaves, Mark J Howard, Daniel R Lloyd, Jeremy S Rossman, C Mark Smales, Anastasios D Tsaousis, Tobias von der Haar, Mark N Wass, Martin Michaelis   +39 more
doaj   +5 more sources

Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer [PDF]

Scientific Reports
Oxaliplatin resistance remains a major challenge in colorectal cancer (CRC) treatment. We investigated the FBXL5/IREB2/TFRC axis in ferroptosis-mediated resistance reversal.
Miaomiao Wang, Ruizhe Zhang, Shuang He, Feifei Wen, Xiaojie Yu, Xiaoyang Xu, Yangyang Li, Shuhua Wu   +7 more
doaj   +2 more sources

TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell [PDF]

Canadian Journal of Gastroenterology and Hepatology, 2021
Background. Oxaliplatin is the first-choice chemotherapy method for patients with advanced colon cancer. However, its resistance leads to treatment failure for many patients.
Guoqiong Lei, Sushun Liu, Xin Yang, Chao He   +3 more
doaj   +3 more sources

UBAP2L-driven stress granule formation links oxaliplatin resistance to gastric cancer [PDF]

Communications Biology
Stress granules (SGs), which are phase-separating organelles that serve as protective cellular mechanisms in response to various harmful stimuli, have an unclear role in oxaliplatin resistance.
Chaorui Wu, Yu Yan, Qichen Chen, Zhiying Lian, Jiayong He, Ruoyu Ling, Xuetao Lei, Yanmei Peng, Boyang Zheng, Qingbin Yang, Gengtai Ye, Wenhui Ma, Guoxin Li   +12 more
doaj   +2 more sources

NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines [PDF]

Molecular Cancer, 2011
Background YB-1 is a multifunctional protein that affects transcription, splicing, and translation. Overexpression of YB-1 in breast cancers causes cisplatin resistance. Recent data have shown that YB-1 is also overexpress in colorectal cancer.
Tsofack Serges P, Garand Chantal, Sereduk Chris, Chow Donald, Aziz Meraj, Guay David, Yin Hongwei H, Lebel Michel   +7 more
doaj   +3 more sources

Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer [PDF]

Cancer Medicine
Background Oxaliplatin, a third‐generation platinum‐based chemotherapeutic agent, is widely used in the treatment of colorectal cancer (CRC). However, some patients do not respond effectively to oxaliplatin, and intrinsic resistance to the drug poses a ...
Reio Ueta, Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Chikashi Ishioka   +5 more
doaj   +2 more sources

The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer [PDF]

Pharmaceuticals
Background/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism was proposed.
Xiaoqing Wang, Meili Xi, Xing Lu, Xiangshi Tan   +3 more
doaj   +2 more sources

Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis [PDF]

Molecular Medicine
Background Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in ...
Yan Zhang, Jian Cao, Zheng Yuan, Jiahui Zhou, Hao Zuo, Xinsheng Miao, Xinhua Gu   +6 more
doaj   +2 more sources